Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that it has filed four petitions for Inter Partes Review (“IPR”) in the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE